Inivata: New Review of ctDNA Liquid Biopsies in Nature

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
422
Inivata: New Review of ctDNA Liquid Biopsies in Nature Reviews Cancer Co-Authored by Inivata CSO Nitzan Rosenfeld

 

New Review of ctDNA Liquid Biopsies in Nature Reviews Cancer Co-Authored by Inivata CSO Nitzan Rosenfeld

Research Triangle Park, NC and Cambridge, UK 24 February 2017 -- Inivata , a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, today announces the publication of a new review of the use of ctDNA as a liquid biopsy for cancer treatment in the journal Nature Reviews Cancer co-authored by Inivata's Chief Scientific Officer and Founder Nitzan Rosenfeld and Co-Founder and Clinical Advisor James Brenton.

In "Liquid biopsies come of age: towards the implementation of circulating tumour DNA" (available online at www.nature.com/nrc/journal/vaop/ncurrent/full/nrc.2017.7.html ) the authors* review the potential of ctDNA in cancer diagnosis, treatment selection and monitoring disease burden. They also highlight the importance of assay sensitivity, as sampling often yields low concentrations of ctDNA, and review currently available approaches for sensitive detection.

The authors conclude that liquid biopsies have demonstrated broad potential clinical utility across a range of applications and they are beginning to be used for patient benefit.

*Jonathan C.M. Wan 1,2 , Charles Massie 1,2 , Javier Garcia-Corbacho 3 , Florent Mouliere 1,2 , James D. Brenton 1,2 , Carlos Caldas 1,2,4 , Simon Pacey 2,4 , Richard Baird 2,4 and Nitzan Rosenfeld 1,2 .

1 Cancer Research UK Cambridge Institute, 2 Cancer Research UK Cambridge Centre, 3 Clinical Trials Unit, Clinic Institute of Haematalogical and Oncological Diseases, Hospital Clinic de Barcelona, 4 Department of Oncology, University of Cambridge Hutchison-MRC Research Centre.

About Nitzan Rosenfeld Nitzan Rosenfeld is a senior group leader at the Cancer Research UK Cambridge Institute, University of Cambridge, and Inivata's co-founder and CSO. Nitzan trained in Physics, and specialized in quantitative molecular biology, obtaining a Ph.D. in the field of Systems Biology from the Weizmann Institute of Science. In 2005 he joined Rosetta Genomics Ltd, where he was head of Computational Biology and led development of molecular diagnostic tests. In 2009 Nitzan joined Cancer Research UK's Cambridge Institute. His research group combines molecular technologies with genomic approaches to develop new diagnostic strategies. The focus of current research, the application of circulating tumour DNA for personalised cancer diagnostics, formed the basis of Inivata. In 2013 Nitzan was awarded the CRUK Future Leaders in Cancer Research prize, the British Association for Cancer Research Translational Research Award, and a prestigious ERC Starting Grant.  At the end of 2015, Nitzan received the Foulkes Medal which is awarded biennially to an outstanding bioscience researcher within ten years of completing their PhD.

About Inivata Inivata, a clinical cancer genomics company, is employing the precision of ctDNA analysis to improve personalized healthcare in oncology. Using a simple blood test, ctDNA analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment. Inivata's proprietary technology is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. Inivata's Invision ctDNA assay provides a highly sensitive analysis of a highly-select gene panel to identify actionable mutations for oncologists to treat their patients optimally. In 2016, Inivata opened a CLIA lab in Research Triangle Park, NC and launched a large-scale, prospective clinical validation study of the Company's ctDNA analysis in lung cancer. For more information and a full listing of investors, please go to www.inivata.com . Follow us on Twitter @Inivata.

Media Contacts:

Consilium Strategic Communications Chris Gardner/Laura Thornton Email: inivata@consilium-comms.com Phone: +44 (0)20 3709 5700

Karen Chandler-Smith karen.chandler-smith@inivata.com +44 (0)7900 430235

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 50

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Univers Partners to Propel Physical AI Across Industries

Updated Category News Views 145

Univers Sets Sights on Global Physical AI Expansion Now here's a tune we've been humming for a while—AI is coming to take over the mundane, and Univers seems to think it's got the right band together to make that a full-blown concert in the built environment. Announced right in the heart of Antalya, Türkiye, at the esteemed COP31, we're seeing Univers grab hands with...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 25

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 159

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 83

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 155

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 10

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 19

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 101

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 104

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking Solutions: The N-SISS Fellowship for Innovators

Updated Category News Views 146

Applications Open for the N-SISS Fellowship Innovative research incubator focused on eliminating negative health outcomes Are you a doctoral-level nurse scientist or engaged in related fields like public health and social sciences? The Institute for Policy Solutions (IPS) is thrilled to announce the opening of applications for the next cohort of the Nursing Science...

Continue Reading
Jump Global Media Expands Portfolio with Major Acquisition

Updated Category News Views 694

Jump Global Media's Strategic Acquisition Jump Global Media Group UK Ltd. (Jump GMG), a leading multi-platform entertainment company, has made a significant move in the film and television industry by acquiring the rights to The Empress and I, a compelling memoir penned by renowned author Donna Stein. The Story Behind the Memoir The Empress and I narrates an extraordinary...

Continue Reading
VIVO Agency Welcomes Jennifer Mugnaini as New EVP of Services

Updated Category News Views 126

VIVO Agency Appoints Jennifer Mugnaini as EVP of Client Services Strategically enhancing client leadership and driving growth, VIVO Agency has named Jennifer Mugnaini as the new Executive Vice President of Client Services. With more than twenty years of extensive experience in healthcare and MedTech marketing, Jen is poised to elevate the agency's client service teams,...

Continue Reading
IMU Biosciences Welcomes Dr. Carlos Paya to Its Board

Updated Category News Views 197

IMU Biosciences Welcomes Dr. Carlos Paya as Non-Executive Director IMU Biosciences, a pioneering biotechnology company focused on innovating how the immune system is understood and treated, has recently bolstered its leadership team. The company is thrilled to announce the appointment of Dr. Carlos Paya as a Non-Executive Director. His extensive experience in both...

Continue Reading
Significant Impact of Older Voters in Pittsburgh's Future

Updated Category News Views 225

Older Voters in Pittsburgh: A Key Factor in the Upcoming Election In the vibrant city of Pittsburgh, voters aged 50 and older are gearing up to play a crucial role in the next mayoral election. Recent insights reveal that this demographic not only makes up a substantial percentage of the voting public, but they are also highly engaged on critical issues that impact their...

Continue Reading